To hear about similar clinical trials, please enter your email below
Trial Title:
A Study of Immunotherapy Treatment in People With Sarcoma
NCT ID:
NCT06113315
Condition:
Sarcoma
Conditions: Official terms:
Sarcoma
Conditions: Keywords:
Immunotherapy
Immune Blockade-Based Therapy
23-254
Study type:
Observational
Overall status:
Enrolling by invitation
Study design:
Time perspective:
Prospective
Summary:
The purpose of this study is to collect information from participants' medical records to
improve our knowledge about immunotherapy use and how effective it is as a treatment for
people with sarcoma. Immunotherapy drugs boost the immune system's ability to fight
cancer by blocking proteins that act as a "brake" on the immune system. Blocking these
proteins is like releasing the brakes, so that the immune system can target cancer cells
and destroy them. This action is sometimes described as "immune checkpoint blockade.
Criteria for eligibility:
Study pop:
Patients with sarcoma treated with immune checkpoint blockade (ICB; anti-PD-1, PD-L1,
and/or CTLA-4) based therapy at Memorial Sloan Kettering Cancer Center (MSK).
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- Participants must have a histologic diagnosis of sarcoma confirmed by an MSK
pathologist.
- Any prospectively identified patient being treated or to be treated with an immune
checkpoint inhibitor, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-LAG3
inhibitor, either as monotherapy or in combination with additional systemic therapy
o Novel immune checkpoints inhibitors that are developed after submission of this
protocol will also be included) Please Note: there is no age requirement. Patients
of all ages are eligible to enroll
Exclusion Criteria:
- Patient unwilling to consent to collection of historical and longitudinal
clinicopathologic data in the patient medical record from baseline (the period prior
to ICB initiation), during, and after ICB treatment
Gender:
All
Minimum age:
N/A
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
Address:
City:
Basking Ridge
Zip:
07920
Country:
United States
Facility:
Name:
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Address:
City:
Middletown
Zip:
07748
Country:
United States
Facility:
Name:
Memorial Sloan Kettering Bergen (All Protocol Activities)
Address:
City:
Montvale
Zip:
07645
Country:
United States
Facility:
Name:
Memorial Sloan Kettering Cancer Center Suffolk- Commack (All Protocol Activities)
Address:
City:
Commack
Zip:
11725
Country:
United States
Facility:
Name:
Memorial Sloan Kettering Westchester (All Protocol Activities)
Address:
City:
Harrison
Zip:
10604
Country:
United States
Facility:
Name:
Memorial Sloan Kettering Cancer Center
Address:
City:
New York
Zip:
10065
Country:
United States
Facility:
Name:
Memorial Sloan Kettering Nassau (All Protocol Activities)
Address:
City:
Uniondale
Zip:
11553
Country:
United States
Start date:
October 27, 2023
Completion date:
October 2028
Lead sponsor:
Agency:
Memorial Sloan Kettering Cancer Center
Agency class:
Other
Source:
Memorial Sloan Kettering Cancer Center
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06113315
http://www.mskcc.org/mskcc/html/44.cfm
